Starjemza (ustekinumab-hmny) was approved by the FDA this week as a biosimilar to Stelara. 2 A pair of clinical trials ...

The FDA designates 2 biosimilars as interchangeable, enhancing access to treatments for inflammatory diseases and multiple ...

Advanz Pharma secures exclusive rights from Alvotech to commercialize three biosimilar candidates in Europe in addition to previously partnered programsThe agreement includes proposed biosimilars to ...

Johnson & Johnson (J&J) has received approval from the Medicines and Healthcare products Regulatory Agency (MHRA) for its ...

Janssen-Cilag Limited has received approval from the Medicines and Healthcare products Regulatory Agency (MHRA) for ...

The Medicines and Healthcare products Regulatory Agency (MHRA) has approved guselkumab (Tremfya) for the treatment of Crohn’s ...

Despite this, real-world data comparing guselkumab and risankizumab effectiveness and safety are quite limited. In the literature, Ruggiero et al. and Viopulus et al. compared the efficacy and safety ...

The U.K.’s Medicines and Healthcare products Regulatory Agency has approved guselkumab, or Tremfya, to treat Crohn’s disease and ulcerative colitis. Guselkumab is currently approved to treat ...

The Medicines and Healthcare products Regulatory Agency (MHRA) has today, 16 May 2025, approved guselkumab (Tremfya) to treat Crohn's disease and ulcerative colitis (UC). Guselkumab is currently ...

The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) has approved Tremfya (guselkumab) (Tremfya) to treat Crohn’s disease and ulcerative colitis (UC). The approval was granted to ...

Royalty Pharma's current portfolio includes royalties on more than 35 commercial products, including Vertex's Trikafta, GSK's Trelegy, Roche's Evrysdi, Johnson & Johnson's Tremfya, Biogen's Tysabri ...

Treatment with guselkumab in patients with plaque psoriasis was associated with improvements in 3 biomarkers, yet greater improvements were seen with adalimumab and similar improvements were seen with ...